Psychiatry

Check out the top 5 psychiatry headlines in August 2025, including the fast-track designation of NRX-100 for suicidal ideation.

The 9-week intervention targeting positive psychological wellbeing in IBS was feasible, well-accepted, and linked to improvements in IBS-related outcomes.

Up to half of psoriasis patients report significant psychiatric symptoms, highlighting the importance of routine screening in practice.

Any alcohol intake was linked to a greater risk of liver mortality, but healthy diet and physical activity lowered this risk across all drinking patterns.

Phase 2 data shows meaning-centered psychotherapy may strengthen psilocybin-assisted therapy for depression in patients with cancer and MDD.

In a study, ADHD treatments were linked to reduced suicidal behavior, substance misuse, transport accidents, and criminality, but not accidental injuries.

Stay updated with the latest healthcare breakthroughs, including FDA news and new cardiology research, in this week's essential news roundup.

In a new study, esketamine nasal spray improved anhedonia in treatment-resistant unipolar and bipolar depression, independent of general symptom changes.

A recent study shows combined treatment increases total and N3 sleep in just 3 days for patients with comorbid insomnia and depression.

Single-dose psychedelic therapy (RE104 30 mg) shows rapid improvements in postpartum depression, offering a potential alternative to slow-acting therapies.

Phase 4 data reveal esketamine outperforms standard antidepressants in reducing insomnia and boosting next-day well-being in patients with TRD.

FDA grants Fast Track to NRX-100, the first preservative-free IV ketamine, for treating suicidal ideation in depression.

Co-locating ID screening in an inpatient SUD program resulted in timely identification of and linkage to care for viral hepatitis and latent tuberculosis.

Kratom poses serious addiction risks despite its natural appeal, misleading many into believing it's a safe alternative for pain and withdrawal relief.

This July psychiatry month in review features FDA news, depression trials, links between healthy habits and mental health, and SoCal Psych 2025 highlights.

A new study found patients with HS are significantly more likely to develop new-onset depression and anxiety, regardless of disease severity.

Findings suggest 7000 steps per day is associated with a reduced risk of health outcomes including mortality, cardiovascular disease, and type 2 diabetes.

Phase 4 trial shows esketamine provides significant symptom relief in patients with treatment-resistant depression within 24 hours of the first dose.

A new study found older adults with insomnia experience significantly greater and longer-lasting depressive symptoms after inflammatory exposure.

Psychiatrists at the 2025 So Cal Psych Conference shared evidence-based tools and therapies to improve mental health outcomes for new mothers.

In this Q&A, Alva discusses how to identify tardive dyskinesia, approaches for treatment-resistant depression, and emerging therapies.

At 2025 So Cal Psych, Maguire shared insights on diagnosing bipolar depression, treating agitation in dementia, and managing mental health challenges in patients who stutter.

Patients who adhered to a strict 12-week low FODMAP diet saw improvements in fatigue, anxiety, and depression, and performed better on an attention test.

At So Cal Psych 2025, Monroe discusses the promise of xanomeline-trospium (Cobenfy) and its novel mechanism.

Discover the latest insights on tardive dyskinesia treatment, diagnosis, and the role of VMAT2 inhibitors in enhancing patient well-being.